Back to top

crispr: Archive

Zacks Equity Research

CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.

VRTXNegative Net Change CRSPPositive Net Change GMABPositive Net Change IMCRPositive Net Change